Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops could replace reading glasses for presbyopia

NCT ID NCT05728944

Symptom relief Sponsor: LENZ Therapeutics, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tested LNZ101 eye drops in 229 people aged 45-75 with presbyopia, a condition that makes it hard to see up close. The drops combine aceclidine and brimonidine to temporarily improve near vision. The main goal was to see if participants could read three lines better on an eye chart without losing distance vision. The study is complete, offering hope for a non-surgical option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Aceclidine and brimonidine combination eye drops
What this could lead to
If it works, this could offer a non-surgical, temporary fix for reading vision in people with presbyopia.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to everyone. The effect is temporary and requires repeated use. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

229 people

The number who actually took part.

Started

Mar 2023

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subjects MUST: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study visits; 3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1; 4. Have +1.00 to -4.00 diopter (D) of sphere calculated in minus cylinder (so that spherical equivalent (SE) results in myopia no more severe than -4.00 D MRSE) in both eyes determined by manifest refraction documented at Visit 1; 5. Have ≤2.00 D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1; 6. Be presbyopic as determined at Visit 1 Exclusion Criteria: Subjects must NOT: 1. Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy; 2. Have known contraindications or sensitivity to the use of any of the study medications or their components; 3. Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye; 4. Have moderate or severe dry eye defined as total central corneal fluorescein staining in either eye at Visit 1; 5. Have clinically significant abnormal lens findings including early lens changes during dilated slit lamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eye diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

eye disorder myopia presbyopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eye diseases Near vision Presbyopia Refractive error

Contacts and locations

Locations

  • Site #203

    Newport Beach, California, 92663, United States

  • Site #204

    Danbury, Connecticut, 06810, United States

  • Site #205

    Crystal River, Florida, 34429, United States

  • Site #207

    Powell, Ohio, 43065, United States

  • Site #208

    St Louis, Missouri, 63128, United States

  • Site #209

    Dothan, Alabama, 36301, United States

  • Site #211

    Louisville, Kentucky, 40206, United States

  • Site #212

    West Fargo, North Dakota, 58078, United States

  • Site #213

    Eugene, Oregon, 97401, United States

  • Site #214

    La Jolla, California, 92037, United States

  • Site #215

    Bozeman, Montana, 59718, United States

  • Site #216

    Scottsdale, Arizona, 85260, United States

  • Site #217

    Warwick, Rhode Island, 02888, United States

  • Site #218

    Northbrook, Illinois, 60062, United States

  • Site #219

    Dover, New Jersey, 07801, United States

  • Site #220

    Glendale, California, 91204, United States

  • Site #221

    Rochester, New York, 14626, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.